AVASTIN (bevacizumab), monoclonal antibody - CERVICAL CANCER
ONCOLOGY - Focus
Opinions on drugs - Posted on Oct 12 2016
Reason for request
Extension of Inclusion
- AVASTIN has Marketing Authorisation in adults with persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin (or in combination with paclitaxel and topotecan in those who cannot receive platinum-based treatment).
- The addition of bevacizumab to chemotherapy has demonstrated a moderate effect on overall survival, but with reservations about the strength of the results and at the cost of accrued toxicity, especially recto-vaginal fistulas, compared to chemotherapy by carboplatin and paclitaxel.
Clinical Added Value
Évaluation des médicaments
HAS opinions and decisions